Abstract |
A retrospective clinical review of 41 patients with chronic myelomonocytic leukemia revealed a median age of 66 years and a male:female ratio of 2.4:1. The disease was preceded by a myelodysplastic syndrome of a different subtype in 24% of the patients and transformed into acute leukemia in 24%. Splenomegaly was present in 54% of the patients and reached massive proportions in 24%. Chromosomal abnormalities occurred in 34% of those studied, most commonly in the younger age group; the most frequent were trisomy 8, monosomy 7, and deletions involving the long arms of chromosomes 20 and X. Polyclonal hypergammaglobulinemia was detected in 47% of the patients in whom serum protein electrophoresis was done. The median survival was 3 years. With use of univariate analysis, the statistically significant prognostic determinants were hemoglobin level, the "modified Bournemouth score," and bone marrow blast cell percentage. When these factors were subjected to a multivariate analysis, only bone marrow blast cell percentage was an independent prognostic determinant. Orally administered hydroxyurea controlled leukocytosis and splenomegaly in some patients without affecting the overall prognosis.
|
Authors | A Tefferi, H C Hoagland, T M Therneau, R V Pierre |
Journal | Mayo Clinic proceedings
(Mayo Clin Proc)
Vol. 64
Issue 10
Pg. 1246-54
(Oct 1989)
ISSN: 0025-6196 [Print] England |
PMID | 2593715
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chromosome Aberrations
- Chromosome Disorders
- Female
- Humans
- Infant
- Leukemia, Myelomonocytic, Chronic
(diagnosis, genetics, mortality)
- Leukocytes
- Male
- Middle Aged
- Myelodysplastic Syndromes
(complications)
- Prognosis
- Splenomegaly
(complications)
- Stem Cells
|